Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

National Survey Finds Six In Ten Americans Believe Serious Outbreak Of Influenza A (H1N1) Likely In Fall/Winter
As part of a series about Americans" response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans" views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.
generic viagra online
Brazil's Scientific Research On The Rise, Thomson Reuters Study Finds
Thomson Reuters today announced the results of a study documenting Brazil"s steady rise during the last two decades in both the volume and impact of its scientific work. According to Science Watch, these findings underscore Brazil"s standing among the emergent "BRIC" nations. BRIC -- an acronym for Brazil, Russia, India and China -- are the countries possessing the res and economic potential to capture a significant share of the world"s future economic growth.
News of the day
Blood Pressure Association Comment On BMJ Research Paper
UK charity the Blood Pressure Association has responded to the BMJ research paper "Use of blood pressure lowering drugs in the prevention of cardiovascular disease":
Mental Health

Shire Selects SAS(R) Drug Development To Handle Clinical Trials Data

SAS, the leader in business analytics, announced that Shire, the global specialty biopharmaceutical company, has selected SAS® Drug Development as the platform for its clinical trials data. "Shire is excited about our partnership with SAS, and we look forward to leveraging the SAS Drug Development platform to manage our clinical trial data," said Nick Ronca, Associate Director Clinical R&D, Shire Pharmaceuticals. SAS Drug Development is available as a standalone or hosted solution with access via a secure, thin client. A centralized repository allows life sciences firms to aggregate, analyze and review clinical trials data to determine safety and efficacy outcomes. "Our approach at SAS allows our customers, like Shire, to be more focused and efficient in developing and delivering medicines to patients and their families around the world," said Jason Burke, Global Director of Health and Life Sciences for SAS. 21 CFR and CDISC Compliant SAS Drug Development allows rapid and reliable validation and implementation, eliminating strain on limited IT infrastructure and res. The solution is compliant with global agency regulations, such as 21 CFR Part 11, which is often difficult to attain. "Our hosted global environment contains a single view of the targeted clinical data in a secured and qualified environment so scientists, programmers and statisticians can view the most up-to-date, accurate information" said Burke. SAS" scalability and flexibility were features important to Shire, which has grown rapidly through acquisitions and mergers over its nearly twenty-five year history. Shire, which has a presence in 23 countries and markets medicines in more than 45 countries, needed a global solution for managing and processing its clinical trial data. "Working in unison with SAS allows Shire to focus on meeting its mission, and investing in its product portfolio instead of developing a complex IT infrastructure to support clinical data," said Burke. SAS Implementation Team Relying on the SAS Consulting Group that has successfully deployed SAS Drug Development in the past, Shire believes that the system will maximize the best practices of both Shire and SAS. SAS is demonstrating SAS Drug Development at the DIA 45th Annual Meeting in Booth 301. SAS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009